Colorectal Cancer
Conditions
Brief summary
Currently, no adjuvant study with hepatic arterial infusion in the adjuvant setting is opened. Recently, the results of a phase II study (NCT00268463, NSABP-C-09) assessing the potential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR, after resection of CRLM have been reported. The primary end point was 2-year survival. Fifty-five of 76 eligible patients were able to initiate protocol-directed therapy and completed median of six cycles (range, one to six). Three postoperative or treatment-related deaths were reported. Overall, 88% of evaluable patients were alive at 2 years. With a median followup of 4.8 years, a total of 30 patients have had disease recurrence, 11 involving the liver. Median disease-free survival was 32.7 months. In conclusion alternating HAI of FUDR and systemic capecitabine and oxaliplatin met the prespecified end point of higher than 85% survival at 2 years and were clinically tolerable.
Interventions
DRUGOxaliplatin HAI
Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
DRUGOxaliplatin IV
Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
DRUGmFOLFOX6
Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
DRUGLV5FU2
Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
Sponsors
National Cancer Institute, France
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed metastatic colorectal adenocarcinoma, 2. Curative-intent resection (or ablation) R0 of at least 4 CRLM, 3. Preoperative oxaliplatin- and/or irinotecan-based chemotherapy (successively or concomitantly) +/- non experimental biological therapy, e.g., anti-EGFR or antiangiogenic antibody, 4. Confirmed radiological tumor control before surgery (i.e., objective response or stable disease according to RECIST1.1 criteria), 5. WHO performance status of 0 or 1, 6. Age ≥ 18 years, 7. Adequate hematological function: absolute neutrophil count (ANC) \> 2 x 109/L; platelets \> 100 x 10\^\^9/L, hemoglobin (Hb) \> 9 g/dL. 8. Adequate liver function: serum bilirubin \</= 1.5 x ULN; 9. Aminotransferases levels \</= 2.5 ULN (\</= 5 ULN if liver metastases in place), and alkaline phosphatase level ≤ 5 ULN 10. Creatinin clearance ≥ 30 ml/min 11. Informed consent signed by the patient or his/her legal representative. 12. Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization). Both men and women (of childbearing potential) who are sexually active must use adequate contraception, during and for at least 6 months post-treatment.
Exclusion criteria
1. Extrahepatic metastatic disease (except ≤3 lung nodules (≤10 mm on chest CT scan) deemed amenable to curative-intent resection/ablation), 2. Symptomatic primary tumor requiring urgent surgery, asymptomatic primary colorectal tumor is not a non-inclusion criteria if its 3. Contraindication to fluoropyrimidines or oxaliplatin, as mentioned in the SMPC of investigational medicinal products 4. Known dihydropyrimidine dehydrogenase (DPD) deficiency 5. Disease progression during, or early hepatic relapse (\< 6 months) after the end of, oxaliplatin-based adjuvant chemotherapy following primary tumor resection 6. History of hepatic arterial infusion with any treatment (chemotherapy, radioembolisation), 7. Peripheral neuropathy\> grade 1, 8. History of cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix 9. Concomitant administration of cimetidine 10. Concomitant medications/comorbidities that may prevent the patient from receiving study treatments, 11. Patient already included in another clinical trial with an experimental molecule, 12. Pregnancy or lactation, 13. Patients deprived of liberty or under guardianship, 14. Patients unable to undergo medical monitoring test for geographical, social or psychological reasons. 15. Patients must not have any uncontrolled concurrent illness including, but not limited to, severe active or uncontrolled infection, symptomatic congestive heart failure, unstable, angina pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus or psychiatric illness/social situations that would limit compliance with study requirements resection is planned (REVERSE strategy authorized)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 18-month hepatic RFS rate | Assessed 18 months after inclusion |
| 3-year RFS rate | Assessed 3 years after inclusion |
Countries
France
Outcome results
None listed